GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US

Mar 21, 2024 · GSK plc GSK announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rivals …

CouponFollow Extension

$35
OFF

GSK Follows Rivals, To Cap Out-of-Pocket Inhaler Cost In US

1 week from now

Mar 21, 2024 · GSK plc GSK announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rivals …

yahoo.com

$35
OFF

UPDATE 1-GSK To Cap Out-of-pocket Inhaler Costs In US - Yahoo …

1 week from now

March 20 (Reuters) - British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month …

yahoo.com

$35
OFF

GSK To Cap Out-of-pocket Inhaler Costs In US | Reuters

1 week from now

Mar 20, 2024 · British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for …

reuters.com

$35
OFF

GSK Announces Cap Of $35 Per Month On U.S. Patient Out-of …

1 week from now

Mar 20, 2024 · Announcement builds on GSK’s decades-long commitment to making products accessible to those who need them; GSK today announced it will cap out-of-pocket costs for …

gsk.com

$35
OFF

GSK Joins AstraZeneca, Boehringer In Capping US Out-of-pocket …

1 week from now

Mar 21, 2024 · Each drugmaker is capping out-of-pocket costs at $35 per month for their respective inhaler products. GSK's new price cap will take effect no later than January 1, …

fiercepharma.com

$35
OFF

GSK Follows Rivals, To Cap Out-of-Pocket Inhaler Cost In US

1 week from now

Mar 21, 2024 · GSK plc (GSK Quick Quote GSK - Free Report) announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, …

zacks.com

$35
OFF

GSK To Cap Out-of-pocket Inhaler Costs In US

1 week from now

Mar 21, 2024 · British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for …

bworldonline.com

$35
OFF

GSK To Cap Out-of-pocket Inhaler Costs In US – PM360

1 week from now

Mar 21, 2024 · (Reuters) -British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month …

pm360online.com

$35
OFF

GSK To Cap Asthma, COPD Inhaler Costs To $35 Per Month For …

1 week from now

Mar 25, 2024 · The out-of-pocket costs for GSK asthma and chronic obstructive pulmonary disease (COPD) inhalers will be capped at $35 per month for eligible patients, according to the …

pulmonologyadvisor.com

$35
OFF

AstraZeneca To Cap Out-of-pocket Inhaler Costs In US, Following …

1 week from now

Mar 18, 2024 · Drugmaker AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States from June, following a …

reuters.com

$35
OFF

GSK Announces Cap Of $35 Per Month On U.S. Patient Out-of …

1 week from now

Mar 20, 2024 · GSK today announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all of its asthma and chronic obstructive pulmonary disease …

industryintel.com

$35
OFF

GSK To Cap Out-of-pocket Inhaler Costs In US - KFGO

1 week from now

Mar 20, 2024 · (Reuters) – British pharmaceutical giant GSK said on Wednesday it will cap out-of-pocket costs at $35 per month for all its inhaled asthma and chronic lung disease medicines …

kfgo.com

$35
OFF

Inhaler Cost Cap Trend Could Help Avoid Lawsuits, Expert Says

1 week from now

Mar 22, 2024 · GlaxoSmithKline is the latest company to join two others in capping out-of-pocket costs for its inhaler products at $35 per month, the company announced Wednesday (March …

insidehealthpolicy.com

$35
OFF

Senator Claims GSK Pulled Popular Asthma Med To Dodge Inhaler …

1 week from now

May 3, 2024 · Toward the end of March, GSK followed in the footsteps of Boehringer Ingelheim and AstraZeneca when it pledged to cap out-of-pocket costs for its inhalers at $35 per month …

fiercepharma.com

FAQs about GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US Coupon?

Will GSK cap out-of-pocket costs for inhaled asthma & chronic lung disease?

REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights March 20 (Reuters) - British pharmaceutical giant GSK (GSK.L) said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for eligible patients in the United States, following similar moves by two of its rivals. ...

What is the GSK out-of-pocket price cap?

The out-of-pocket price cap will provide a significant benefit to patients taking these medicines whose monthly costs currently exceed $35. Maya Martinez-Davis, President, U.S. Commercial, GSK said: “GSK is committed to bringing innovation and accessibility to patients with respiratory illnesses. ...

Is GSK capping patients' monthly payments for COPD Meds?

(GlaxoSmithKline) Amid congressional scrutiny on U.S. inhaler prices, GSK is the latest pharma giant to commit to capping patients' monthly payments for its portfolio of asthma and chronic obstructive pulmonary disease (COPD) meds. The move follows similar announcements from GSK's peers Boehringer Ingelheim and AstraZeneca. ...

How much does GSK cost per month?

GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025. ...

Which inhaler manufacturers have committed to a $35 price cap?

With the move, three leading inhaler manufacturers have committed to the $35 out-of-pocket monthly price cap. A fourth drugmaker, Teva, was also included in the HELP committee’s January investigation into the “outrageous” costs for asthma and COPD products on the U.S. market. ...

Does GSK have a COPD cap?

This cap would apply to all of GSK’s asthma and chronic obstructive pulmonary disease (COPD) inhalers, which include Advair Diskus, Advair HFA, Anoro Ellipta, Breo Ellipta and Trelegy Ellipta. However, GSK plans to start this in 2025. The British drugmaker is one of the biggest sellers of inhalers in the United States. ...